Gennex Laboratories has been awarded by the Drugs Control Administration, Government of Telangana, certificate for Good Manufacturing Practices (GMP) in the manufacturing and quality control operations as recommended by the World Health Organization, for a period of 2 years. This certificate has been awarded after inspection of its manufacturing facility by the Joint Inspection Team of officers from Central Drugs Standard Control Organization and Drugs Control Administration, Telangana with regard to the company’s adherence to manufacturing and quality control norms of World Health Organization. This award will provide a cutting-edge to penetrate European market in future.
Secondly, the company has also received Consent for Operations (CFO) from the Telangana State Pollution Control Board (TSPCB) for a further period of 5 years after a team of officers who inspected the company’s manufacturing and effluent treatment facilities recorded its satisfaction. The company, however, continues to make efforts to ensure that the Pollution Control norms are strictly adhered to and necessary measures taken from time to time.
Further, the Drugs Control Administration, Telangana had on May 06, 2017, approved new product namely Flupentixol Hydrochloride and issued the Drug Licence for the same. The new product is an anti-depressant drug that goes in combination with Melitracin hydrochloride and is widely in demand notably in countries like Bangladesh.
Gennex Laboratories is an integrated pharmaceutical company and has a product portfolio spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The company is engaged in manufacturing of bulk drugs, intermediates and biotech products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: